Consolidative Immunotherapy in Unresectable Stage III NSCLC With Oncogenic Drivers

Published: May 15, 2024, 4 a.m.

Host: Joshua E. Reuss, MD
\n\n\n \n

In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.